Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-2475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
This trial is available at multiple Sutter Locations. Please contact one of the following about Study S2302-Pragmatica:
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
PAMF/Fremont: Tanya Pozniansky pozniat@sutterhealth.org
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: SIMR@sutterhealth.org
Modesto: Stephanie Edmondson edmondsons@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals1@sutterhealth.org
San Mateo: Stephanie Casal CasalSL@sutterhealth.org and Bonnie Chan ChanBW@sutterhealth.org
Principal Investigator
Related Studies
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Investigator: Jiang Li, Ph.D., MPH